ABVC BioPharma Inc (ABVC)
0.61
-0.01
(-1.61%)
USD |
NASDAQ |
Mar 24, 16:00
0.60
-0.01
(-1.64%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 19.58M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -73.62% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 51.90 |
| Price to Book Value | 3.308 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3153 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
03/20 07:00
MT Newswires
03/14 10:27
Yahoo
03/14 07:00
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
Yahoo
02/23 16:16
Globe Newswire
02/21 08:30
Globe Newswire
01/19 08:30
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 03/31/2023* | -- | Results | Q4 2022 | -- | -- | -- | |
| 08/15/2022 | -- | Results | Q2 2022 | -- | -- | -- | |
| 05/16/2022 | -- | Results | Q1 2022 | -- | -- | -- | |
| 03/31/2022 | -- | Results | Q4 2021 | -- | -- | -- | |
| 11/15/2021 | -- | Results | Q3 2021 | -- | -- | -- | |
| 08/12/2021 | -- | Results | Q2 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. |
| URL | https://www.abvcpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Mar. 31, 2023 (est.) |
| Last Earnings Release | Aug. 15, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | 0.343M |
| Total Expenses (TTM) | 18.67M |
| Net Income (TTM) | -19.49M |
| Total Assets (Quarterly) | 10.48M |
| Total Liabilities (Quarterly) | 4.787M |
| Shareholders Equity (Quarterly) | 5.919M |
| Cash from Operations (TTM) | -9.462M |
| Cash from Investing (TTM) | -1.212M |
| Cash from Financing (TTM) | 8.520M |
Ratings
Profile
Edit
| ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. |
| URL | https://www.abvcpharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Mar. 31, 2023 (est.) |
| Last Earnings Release | Aug. 15, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ABVC Tweets |